Metastatic Pancreatic Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight's, "Metastatic Pancreatic Cancer Pipeline Insight 2024" report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Metastatic Pancreatic Cancer pipeline landscape. It covers the Metastatic Pancreatic Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Pancreatic Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Metastatic Pancreatic Cancer Research. Learn more about our innovative pipeline today! @ Metastatic Pancreatic Cancer Pipeline Outlook [https://www.delveinsight.com/sample-request/metastatic-pancreatic-cancer-mpc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Metastatic Pancreatic Cancer Pipeline Report

* June 2024:- TME Pharma AG-An Open-label Phase 2 Study of Olaptesed Pegol (NOX-A12) Combined With Pembrolizumab and Nanoliposomal Irinotecan/5-FU/Leucovorin or Gemcitabine/Nab-paclitaxel in Microsatellite-stable Metastatic Pancreatic Cancer Patients.
* June 2024:- Cantex Pharmaceuticals- A Phase I/II Open Label Study to Assess Safety and Preliminary Evidence of a Therapeutic Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer. This is an open label study to determine the safety and preliminary evidence of a therapeutic effect of azeliragon in patients refractory to prior treatment of metastatic pancreatic cancer.
* June 2024:- iOnctura- A Phase 1b, Open Label, Dose Escalation Study of IOA-289, an Orally Bioavailable, Selective Autotaxin (ENPP2) Inhibitor Alone and in Combination With Gemcitabine/Nab-paclitaxel in Patients With Metastatic Pancreatic Cancer. The objective of study IOA-289-102 is to evaluate the safety and tolerability of escalating doses of IOA-289 in patients with metastatic pancreatic cancer in combination with standard chemotherapy consisting of gemcitabine and nab-paclitaxel.
* June 2024:- Mirati Therapeutics Inc.- A Phase 1/2 Trial of MRTX849 in Combination With TNO155 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL 2. This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in combination with TNO155 in patients with advanced solid tumors that have a KRAS G12C mutation.
* DelveInsight's Metastatic Pancreatic Cancer pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Metastatic Pancreatic Cancer treatment.
* The leading Metastatic Pancreatic Cancer Companies such as Jiangsu HengRui Medicine, Eleison Pharmaceuticals, Panbela Therapeutics, SynerGene Therapeutics, Salspera, BioLineRx, Ocuphire Pharma, Incyte Corporation, Eli Lilly and Company, Rexahn Pharmaceuticals, AB Science, Takeda Oncology, and others.
* Promising Metastatic Pancreatic Cancer Therapies such as Antroquinonol, MRTX849, Pembrolizumab, Cetuximab, MRTX849, TNO155, Gemcitabine, and others.

Stay informed about the cutting-edge advancements in Metastatic Pancreatic Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ Metastatic Pancreatic Cancer Clinical Trials Assessment [https://www.delveinsight.com/sample-request/metastatic-pancreatic-cancer-mpc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Metastatic Pancreatic Cancer Emerging Drugs

* Motixafortide: BioLineRx

Motixafortide (formerly known as BL-8040/BKT140) is a novel selective inhibitor of the CXCR4 chemokine receptor. CXCR4, is a well validated therapeutic target that is involved in the mobilization and trafficking of hematopoietic stem cells, immune cells and cancer cells from the bone marrow and the lymph nodes to the peripheral blood. Motixafortide is being developed as a platform for several indications including mobilization of hematopoietic stem cells (HSCs) for autologous transplantations, treatment of solid tumors, and other hematological malignancies.

* Fuzuloparib: Jiangsu Hengrui Pharmaceuticals

Fuzuloparib is a small molecule, orally active PARP inhibitor being developed by Jiangsu Hengrui Pharmaceuticals Co for the treatment of solid cancers. Fuzuloparib has been approved in China for the treatment of ovarian cancer (including fallopian tube cancer or primary peritoneal cancer), and phase II and III trials are investigating fuzuloparib for the treatment of other solid cancers, including cancers of the pancreas, breast, prostate and lungs.

* HP518: Hinova Pharmaceuticals

HP518, a highly selective and orally bioavailable chimeric degrader targeting androgen receptor (AR) with the potential to overcome the drug resistance of prostate cancer due to some specific AR mutations. In discovery and preclinical studies, HP518 showed high degradation activity against wild type AR and some specific AR mutants that are resistant to enzalutamide, and excellent antitumor activity in xenograft mouse models. HP518 is highly selective for AR.

Learn more about Metastatic Pancreatic Cancer Drugs opportunities in our groundbreaking Metastatic Pancreatic Cancer Research and development projects @ Metastatic Pancreatic Cancer Unmet Needs [https://www.delveinsight.com/sample-request/metastatic-pancreatic-cancer-mpc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Metastatic Pancreatic Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

* Oral
* Intravenous
* Subcutaneous

Metastatic Pancreatic Cancer Products have been categorized under various Molecule types such as

* Small molecule
* Cell Therapy
* Peptides
* Polymer
* Small molecule
* Gene therapy

Discover the latest advancements in Metastatic Pancreatic Cancer Treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ Metastatic Pancreatic Cancer Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/metastatic-pancreatic-cancer-mpc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Metastatic Pancreatic Cancer Pipeline Report

* Coverage- Global
* Metastatic Pancreatic Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Metastatic Pancreatic Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Metastatic Pancreatic Cancer Companies- Jiangsu HengRui Medicine, Eleison Pharmaceuticals, Panbela Therapeutics, SynerGene Therapeutics, Salspera, BioLineRx, Ocuphire Pharma, Incyte Corporation, Eli Lilly and Company, Rexahn Pharmaceuticals, AB Science, Takeda Oncology, and others.
* Metastatic Pancreatic Cancer Therapies- Antroquinonol, MRTX849, Pembrolizumab, Cetuximab, MRTX849, TNO155, Gemcitabine, and others.

For a detailed overview of our latest research findings and future plans, read the full details of Metastatic Pancreatic Cancer Pipeline on our website @ Metastatic Pancreatic Cancer Drugs and Companies [https://www.delveinsight.com/sample-request/metastatic-pancreatic-cancer-mpc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Metastatic Pancreatic Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Metastatic Pancreatic Cancer- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Rucaparib: Eleison Pharmaceuticals
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* MDB 401 B: Panbela Therapeutics
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* SBP 101: Takeda Oncology
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Metastatic Pancreatic Cancer Key Companies
* Metastatic Pancreatic Cancer Key Products
* Metastatic Pancreatic Cancer- Unmet Needs
* Metastatic Pancreatic Cancer- Market Drivers and Barriers
* Metastatic Pancreatic Cancer- Future Perspectives and Conclusion
* Metastatic Pancreatic Cancer Analyst Views
* Metastatic Pancreatic Cancer Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=metastatic-pancreatic-cancer-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/